NoNO's Stroke Trial Could Have Major Implications for Future Treatment

via Toronto-based NoNO announced results from the pivotal Phase III ESCAPE-NA1 trial of intravenous nerinetide in patients with acute ischemic stroke who were chosen to undergo endovascular thrombectomy. The drug, without previous administration of alteplase (Genentech’s Activase), provided medically important improvements in the patients. The results were simultaneously presented at the International Stroke Conference in Los Angeles and published in The Lancet.

article source